Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2014

View Archived Issues

University of Bath patents novel deuterated estradiol derivatives

Novel glucan synthase inhibitors disclosed by Evolva

FDA removes partial clinical hold on vantictumab trials

Acusphere withdraws European MAA for Imagify

EWAS in Alzheimer's patients reveals involvement of ANK1 gene

Researchers develop biomimetic microfluidic model using primary human cells

Preclinical evaluation of novel GPR120 agonist for improved glucose control in obese mice

NIH set to begin phase I safety studies of Ebola virus vaccines

Merck KGaA discloses novel IRAK inhibitors

Nissan Chemical prepares novel JAK inhibitors

Merck KGaA divulges new mGlu4 receptor PAMs

Phase I study of MGCD-516 recruiting patients with solid tumors

Wockhardt's WCK-771 and WCK-2349 receive FDA QIDP status

Darapladib fails to prevent cardiac events in SOLID-TIMI 52 trial

Green Cross begins phase II trial of Hepabig-gene

Clinical investigation of CFZ-533 continues with phase I/II study

Kyowa Hakko Kirin begins Japanese study of KHK-7580 for secondary hyperparathyroidism

Additional NIAID funding supports study of BioCryst's BCX-4430 for Ebola

Senesco closes enrollment in phase Ib/IIa trial of SNS01-T

Telik updates progress of development of 5B1 for gastrointestinal cancers

TGen cleared to open enrollment in glioblastoma trial

FDA approves Vimpat as monotherapy for partial-onset seizures

Vizamyl approved in E.U. for PET imaging of beta-amyloid plaques

European orphan drug designation awarded to AMY-101 for PNH

Four products recently granted orphan drug designation in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...